MedTrace Logo

A Phase 1, Study to Evaluate HTI-2088 Tablet

NCT03203811 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-11-14

No results posted yet for this study

Summary

Single Center, Randomized, Double Blind, Placebo Controlled, Single ascending dose trial at 3 levels. Ten subjects will be enrolled at each dose.

Conditions

Interventions

DRUG

HTI-2088

3 dose levels

DRUG

Placebo

placebo oral tablet

Sponsors & Collaborators

  • Hengrui Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-17
Primary Completion
2017-10-23
Completion
2017-10-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03203811 on ClinicalTrials.gov